Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies

Table 5 Efficacy of endoscopic eradication therapy for Barrett’s esophagus with intramucosal adenocarcinoma

Ref.	Type1	n2	Eradication of T1a	5-yr OS
Ell et al[111]	Prospective	100	99%	98%
Pech et al[112]	Prospective (EMR +/- PDT)	349; HGD 17.5%	97.4% (including HGD)	NA
Pouw et al[113]	Prospective (RFA +/- EMR)	44; HGD up to 27%	100%	NA
Prasad et al[75]	Retrospective (PDT)	132	94%	83%
Pouw et al[114]	Prospective (EMR + RFA)	24; HGD 25%; T1b 8%	100%	NA
Pech et al[95]	Retrospective (EMR +/- APC)	79	98.7%	96%
Van Vilsteren et al[115]	RCT	47; HGD up to 40%	97.9%	NA
Zehetner et al[96]	Retrospective	18	82% (14/17); 3/17 subsequently successfully treated under surveillance	NA
Bulsiewicz et al[92]	Retrospective	29	93%	NA
Ngamruengphong et al[120]	Retrospective	229; HGD 24%	-	60%
Saligram et al[116]	Retrospective	54	96%	89% (over 2 yr)
Pech et al[117]	Prospective	1000	96.3% (including HGD)	91.5%
Haidry et al[104]	Retrospective	63	97.5% (combined with HGD cohort)	NA
Agoston et al[118]	Retrospective	79	86%	NA
Li et al[105]	Retrospective	162	97.5%	NA
Phoa et al[119]	Prospective	132; ND/LGD 8.4%; HGD 30%; T1b 1.7%	92%	NA
Marino et al[121]	Retrospective	856	-	71.8%
Semenkovich et al[74]	Retrospective	1123	-	70%

¹Studies use endoscopic mucosal resection/radiofrequency ablation unless otherwise stated.

²Pure T1a cohort unless otherwise stated.

n: Patient number; APC: Argon plasma coagulation; OS: Overall survival; PDT: Photodynamic therapy; NA: Not application.